Gemigliptin
Gemigliptin (LC15-0444) is a highly selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC50 of 10.3 nM for human recombinant DPP-4. Gemigliptin exhibits potent anti-glycation properties. Gemigliptin can be used for the research of advanced glycation end products (AGE) -related diabetic complications[1][2].
Product Specifications
CAS Number
911637-19-9
Product Name Alternative
LC15-0444
UNSPSC
12352005
Hazard Statement
H302, H335
Target
Dipeptidyl Peptidase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease; Cancer
Assay Protocol
https://www.medchemexpress.com/Gemigliptin.html
Concentration
10mM
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C1N(C[C@@H](N)CC(N2CCC3=C(C(F)(F)F)N=C(C(F)(F)F)N=C3C2)=O)CC(F)(F)CC1
Molecular Formula
C18H19F8N5O2
Molecular Weight
489.36
Precautions
H302, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
DPP-4
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
PAPP-A / Pappalysin-1 (Marker of Atherosclerosis and Aneuploid Fetus) (PAPPA/2717), CF488A conjugate, 0.1mg/mL
